List of immunomodulatory antibodies currently in clinical development and their respective isotypes

AntibodyTargetCompanyLatest active clinical phaseIsotype
IpilimumabCTLA-4BMSApprovedIgG1
TremelimumabCTLA-4MedImmune/AstraZenecaIIIgG2
NivolumabPD-1BMSApprovedIgG4
MK-3475PD-1MerckIIIIgG4
CT-011PD-1CureTechIIIgG1
MPDL3280APD-L1Genentech/RocheIIIAglycosyl IgG1
MEDI4736PD-L1MedImmune/AstraZenecaIIgG1 TM
MDX-1105PD-L1BMSIIgG4
MSB0010718CPD-L1Merck KGaAIIgG1
BMS-663513CD137BMSIIgG4
PF-05082566CD137PfizerIIgG2
TRX518GITRGITR IncIAglycosyl IgG1
MEDI6469OX40MedImmune/AstraZeneca/AgonOXIMouse IgG1
CP-870,893CD40RocheIIgG2
CDX-1127CD27CellDexIIgG1
Lirilumab; IPH2102KIRBMS/Innate PharmaIIIgG4
MGA271B7-H3Macrogenics/ServierIIgG1
AlemtuzumabCD52Genzyme/BayerApprovedIgG1

IgG1 TM = IgG1 triple mutant, which contains 3 point mutations in the Fc domain that reduce the binding affinity of the mAb to FcγRs [30].